GSTM1, GSTT1 and CYP1A1 detoxification gene polymorphisms and susceptibility to smoking-related coronary artery disease: A case-only study

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 621, Issue 1-2, 2007, Pages 106-112

  Manfredi, Samantha ^a   Federici, Chiara ^a   Picano, Eugenio ^a   Botto, Nicoletta ^a   Rizza, Antonio ^a   Andreassi, Maria Grazia ^a  

^a G PASQUINUCCI HOSPITAL   (Italy)

Author keywords

Coronary artery disease risk; Cytochrome P450 1A1 polymorphism; DNA damage; Glutathione S transferases genotypes; Smoking

Indexed keywords

CYTOCHROME P450 1A1; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; DETOXIFICATION; DISEASE SEVERITY; FEMALE; GENE DELETION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

CORONARY ARTERIOSCLEROSIS; CYTOCHROME P-450 CYP1A1; FEMALE; GENE DELETION; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE TRANSFERASE; HUMANS; MALE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK; SEVERITY OF ILLNESS INDEX; SMOKING;

EID: 34447259279     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2007.02.014     Document Type: Article

References (36)

1. US DHHS, Reducing tobacco use: a report of the Surgeon General. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2000, pp. 29-52.
2. Pryor W.A., and Stone K. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann. N.Y. Acad. Sci. 686 (1993) 12-28
3. Cerami C., Founds H., Nicholl I., Mitsuhashi T., Giordano D., Vanpatten S., Lee A., Al-Abed Y., Vlassara H., Bucala R., and Cerami A. Tobacco smoke is a source of toxic reactive glycation products. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 13915-13920
4. McNamara P., and FitzGerald G.A. Smoking-induced vascular disease: a new twist on an old theme. Circ. Res. 89 (2001) 563-565
5. Price J.F., Mowbray P.I., Lee A.J., Rumley A., Lowe G.D., and Fowkes F.G. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur. Heart J. 20 (1999) 344-353
6. Newby D.E., Wright R.A., Labinjoh C., Ludlam C.A., Fox K.A., Boon N.A., and Webb D.J. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation 99 (1999) 1411-1415
7. Barua R.S., Ambrose J.A., Eales-Reynolds L.J., DeVoe M.C., Zervas J.G., and Saha D.C. Dysfunctional endothelial nitric oxide biosynthesis in healthy smokers with impaired endothelium-dependent vasodilatation. Circulation 104 (2001) 1905-1910
8. Califf R.M. Cigarette smoking: how much worse can it get?. Circulation 102 (2000) 1340-1341
9. Penn A., and Snyder C.A. Inhalation of sidestream cigarette smoke accelerates development of arteriosclerotic plaques. Circulation 88 (1993) 1820-1825
10. Lu K.P., and Ramos K.S. Identification of genes differentially expressed in vascular smooth muscle cells following benzo[a]pyrene challenge: implications for chemical atherogenesis. Biochem. Biophys. Res. Commun. 253 (1998) 828-833
11. Andreassi M.G. Coronary atherosclerosis and somatic mutations: an overview of the contributive factors for oxidative DNA damage. Mutat. Res. 543 (2003) 67-86
12. Ramos K.S., and Moorthy B. Bioactivation of polycyclic aromatic hydrocarbon carcinogens within the vascular wall: implications for human atherogenesis. Drug Metab. Rev. 37 (2005) 595-610
13. Izzotti A., D'Agostini F., Bagnasco M., Scatolini L., Rovida A., Balansky R.M., Cesarone C.F., and De Flora S. Chemoprevention of carcinogen-DNA adducts and chronic degenerative diseases. Cancer Res. 54 (1994) 1994s-1998s
14. De Flora S., Izzotti A., Walsh D., Degan P., Petrilli G.L., and Lewtas J. Molecular epidemiology of atherosclerosis. FASEB J. 11 (1997) 1021-1031
15. Van Schooten F.J., Hirvonen A., Maas L.M., De Mol B.A., Kleinjans J.C., Bell D.A., and Durrer J.D. Putative susceptibility markers of coronary artery disease: association between VDR genotype, smoking, and aromatic DNA adduct levels in human right atrial tissue. FASEB J. 12 (1998) 1409-1417
16. Wang X.L., Raveendran M., and Wang J. Genetic influence on cigarette-induced cardiovascular disease. Prog. Cardiovasc. Dis. 45 (2003) 361-382
17. Masetti S., Botto N., Manfredi S., Colombo M.G., Rizza A., Vassalle C., Clerico A., Biagini A., and Andreassi M.G. Interactive effect of the glutathione S-transferase genes and cigarette smoking on occurrence and severity of coronary artery risk. J. Mol. Med. 81 (2003) 488-489
18. Landi M.T., Bertazzi P.A., Shields P.G., Clark G., Lucier G.W., Garte S.J., Cosma G., and Caporaso N.E. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 4 (1994) 242-246
19. Gauderman W.J. Sample size requirements for association studies of gene-gene interaction. Am. J. Epidemiol. 155 (2002) 478-484
20. Wang X.L., Greco M., Sim A.S., Duarte N., Wang J., and Wilcken D.E. Effect of CYP1A1 MspI polymorphism on cigarette smoking related coronary artery disease and diabetes. Atherosclerosis 162 (2002) 391-397
21. Cornelis M.C., El-Sohemy A., and Campos H. Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction. J. Med. Genet. 41 (2004) 758-762
22. Li R., Boerwinkle E., Olshan A.F., Chambless L.E., Pankow J.S., Tyroler H.A., Bray M., Pittman G.S., Bell D.A., and Heiss G. Glutathione S-transferase genotype as a susceptibility factor in smoking-related coronary heart disease. Atherosclerosis 149 (2000) 451-462
23. Wilson M.H., Grant P.J., Hardie L.J., and Wild C.P. Glutathione S-transferase M1 null genotype is associated with a decreased risk of myocardial infarction. FASEB J. 14 (2005) 791-796
24. de Waart F.G., Kok F.J., Smilde T.J., Hijmans A., Wollersheim H., and Stalenhoef A.F. Effect of glutathione S-transferase M1 genotype on progression of atherosclerosis in lifelong male smokers. Atherosclerosis 158 (2001) 227-231
25. Wang X.L., Greco M., Sim A.S., Duarte N., Wang J., and Wilcken D.E. Glutathione S-transferase mu1 deficiency, cigarette smoking and coronary artery disease. J. Cardiovasc. Risk 9 (2002) 25-31
26. Salama S.A., Au W.W., Hunter G.C., Sheahan R.G., Badary O.A., Abdel-Naim A.B., and Hamada F.M. Polymorphic metabolizing genes and susceptibility to atherosclerosis among cigarette smokers. Environ. Mol. Mutagen. 40 (2002) 153-160
27. Girisha K.M., Gilmour A., Mastana S., Singh V.P., Sinha N., Tewari S., Ramesh V., Sankar V.H., and Agrawal S. T1 and M1 polymorphism in glutathione S-transferase gene and coronary artery disease in North Indian population. Indian J. Med. Sci. 58 (2004) 520-526
28. Tamer L., Ercan B., Camsari A., Yildirim H., Cicek D., Sucu N., Ates N.A., and Atik U. Glutathione S-transferase gene polymorphism as a susceptibility factor in smoking-related coronary artery disease. Basic Res. Cardiol. 99 (2004) 223-229
29. Abu-Amero K.K., Al-Boudari O.M., Mohamed G.H., and Dzimiri N. T null and M null genotypes of the glutathione S-transferase gene are risk factor for CAD independent of smoking. B.M.C. Med. Genet. 7 (2006) 38
30. Hayes J.D., and Strange R.C. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 61 (2000) 154-166
31. Andreassi M.G., and Botto N. DNA damage as a new emerging risk factor in atherosclerosis. Trends Cardiovasc. Med. 13 (2003) 270-275
32. Mahmoudi M., Mercer J., and Bennett M. DNA damage and repair in atherosclerosis. Cardiovasc. Res. 71 (2006) 259-268
33. Dusinska M., Ficek A., Horska A., Raslova K., Petrovska H., Vallova B., Drlickova M., Wood S.G., Stupakova A., Gasparovic J., Bobek P., Nagyova A., Kovacikova Z., Blazicek P., Liegebel U., and Collins A.R. Glutathione S-transferase polymorphisms influence the level of oxidative DNA damage and antioxidant protection in humans. Mutat. Res. 482 (2001) 47-55
34. Izzotti A., Cartiglia C., Lewtas J., and De Flora S. Increased DNA alterations in atherosclerotic lesions of individuals lacking the GSTM1 genotype. FASEB J. 15 (2001) 752-757
35. Pope C.A. Epidemiology of fine particulate air pollution and human health: biologic mechanisms and who's at risk? Environ. Health Perspect. 108 Suppl. 4 (2000) 713-723
36. Mastin J.P. Environmental cardiovascular disease. Cardiovasc. Toxicol. 5 (2005) 91-94